X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1716) 1716
Publication (153) 153
Book Review (32) 32
Government Document (22) 22
Book Chapter (13) 13
Patent (6) 6
Dissertation (5) 5
Conference Proceeding (4) 4
Magazine Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1200) 1200
male (799) 799
oncology (697) 697
index medicus (648) 648
prostate cancer (545) 545
refractory prostate-cancer (459) 459
prostatic neoplasms - drug therapy (415) 415
cancer (408) 408
aged (378) 378
chemotherapy (377) 377
middle aged (358) 358
animals (299) 299
prostatic neoplasms - pathology (275) 275
hormone-refractory prostate cancer (262) 262
docetaxel (253) 253
urology & nephrology (247) 247
care and treatment (229) 229
treatment outcome (229) 229
antineoplastic agents - therapeutic use (223) 223
aged, 80 and over (211) 211
pharmacology & pharmacy (207) 207
phase-ii trial (199) 199
female (198) 198
antineoplastic combined chemotherapy protocols - therapeutic use (184) 184
carcinoma (169) 169
neoplasms - drug therapy (168) 168
research (165) 165
drug resistance, neoplasm (149) 149
hormone refractory (149) 149
prostate-specific antigen - blood (148) 148
cell line, tumor (144) 144
hormone refractory prostate cancer (144) 144
therapy (144) 144
metastasis (143) 143
apoptosis (135) 135
adult (128) 128
antineoplastic agents - pharmacology (128) 128
expression (127) 127
hormone-refractory (121) 121
prostatic neoplasms - metabolism (121) 121
clinical trials as topic (118) 118
mitoxantrone (118) 118
bone neoplasms - secondary (113) 113
breast-cancer (109) 109
health aspects (108) 108
medicine & public health (108) 108
mice (107) 107
phase-ii (105) 105
antineoplastic agents, hormonal - therapeutic use (100) 100
mitoxantrone plus prednisone (100) 100
drug therapy (99) 99
prognosis (98) 98
analysis (97) 97
survival (96) 96
androgen receptor (92) 92
immunotherapy (91) 91
tumors (91) 91
cell lung-cancer (90) 90
clinical trials (90) 90
estramustine (90) 90
cells (88) 88
prostatic neoplasms - mortality (87) 87
trial (87) 87
disease progression (86) 86
article (85) 85
refractory solid tumors (85) 85
dose-response relationship, drug (83) 83
adenocarcinoma - drug therapy (81) 81
prednisone (80) 80
prostatic neoplasms - therapy (80) 80
taxoids - administration & dosage (78) 78
prostate (77) 77
prostatic neoplasms - blood (77) 77
androgen antagonists - therapeutic use (76) 76
biochemistry & molecular biology (76) 76
neoplasm metastasis (76) 76
antineoplastic agents (75) 75
survival rate (74) 74
drug administration schedule (73) 73
zoledronic acid (73) 73
survival analysis (72) 72
antigen (71) 71
quality of life (71) 71
antineoplastic combined chemotherapy protocols - adverse effects (70) 70
hematology (70) 70
development and progression (69) 69
medicine, research & experimental (69) 69
hematology, oncology and palliative medicine (68) 68
prostatic neoplasms - genetics (68) 68
antineoplastic agents - adverse effects (67) 67
bone metastases (67) 67
review (67) 67
taxoids - therapeutic use (67) 67
antimitotic agents (66) 66
antineoplastic agents - administration & dosage (66) 66
in-vitro (66) 66
double-blind (65) 65
signal transduction (65) 65
bone neoplasms - drug therapy (64) 64
endocrinology & metabolism (64) 64
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1647) 1647
German (40) 40
Japanese (30) 30
French (25) 25
Russian (20) 20
Spanish (11) 11
Dutch (3) 3
Chinese (2) 2
Czech (2) 2
Italian (2) 2
Polish (2) 2
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 08/2007, Volume 110, Issue 3, pp. 556 - 563
Journal Article
The American Journal of Surgical Pathology, ISSN 0147-5185, 06/2014, Volume 38, Issue 6, pp. 756 - 767
On July 31, 2013, the Prostate Cancer Foundation assembled a working committee on the molecular biology and pathologic classification of neuroendocrine (NE)... 
Prostate adenocarcinonma | Carcinoid | Paneth cell like | Small cell carcinoma | Large cell neuroendocrine carcinoma | SURGERY | SMALL-CELL-CARCINOMA | HORMONE-REFRACTORY DISEASE | ANDROGEN RECEPTOR STATUS | CHROMOGRANIN-A | RADICAL PROSTATECTOMY | PATHOLOGY | carcinoid | large cell neuroendocrine carcinoma | prostate adenocarcinonma | SITU HYBRIDIZATION | small cell carcinoma | NEOPLASTIC HUMAN PROSTATE | ACID-PHOSPHATASE | PROGNOSTIC-SIGNIFICANCE | TRANSCRIPTION FACTOR-I | Immunohistochemistry | Predictive Value of Tests | Prostatic Neoplasms - chemistry | Adenocarcinoma - pathology | Prognosis | Neuroendocrine Tumors - chemistry | Adenocarcinoma - classification | Carcinoma, Large Cell - pathology | Humans | Carcinoma, Acinar Cell - pathology | Paneth Cells - pathology | Male | Prostatic Neoplasms - therapy | Carcinoma, Small Cell - classification | Neoplasms, Complex and Mixed - classification | Cell Differentiation | Adenocarcinoma - chemistry | Neuroendocrine Tumors - pathology | Prostatic Neoplasms - pathology | Biomarkers, Tumor - analysis | Terminology as Topic | Carcinoma, Acinar Cell - classification | Carcinoid Tumor - pathology | Neuroendocrine Tumors - classification | Adenocarcinoma - therapy | Neoplasms, Complex and Mixed - pathology | Prostatic Neoplasms - classification | Carcinoma, Large Cell - classification | Neuroendocrine Tumors - therapy | Paneth Cells - classification | Carcinoma, Small Cell - pathology | Carcinoid Tumor - classification
Journal Article
Journal Article
The Prostate, ISSN 0270-4137, 05/2011, Volume 71, Issue 6, pp. 604 - 614
Journal Article
Cancer, ISSN 0008-543X, 06/2008, Volume 112, Issue 11, pp. 2393 - 2400
Journal Article
Cancer, ISSN 0008-543X, 06/2008, Volume 112, Issue 11, pp. 2393 - 2400
BACKGROUND. Antiandrogen withdrawal is a potential therapeutic maneuver for patients with progressive prostate cancer. This study was designed to examine... 
prostate cancer | secondary hormonal therapy | hormone‐refractory prostate cancer | survival | prognosis | antiandrogen withdrawal | PSA | ANTIGEN DECLINE | TAMOXIFEN | FLUTAMIDE WITHDRAWAL | COMBINATION | DISCONTINUATION | MEGESTROL-ACETATE | ONCOLOGY | METASTATIC BREAST-CANCER | MEN | hormone-refractory prostate cancer
Journal Article